Claire Wainwright

Q: What Schools Are Affiliated With Claire Wainwright

Claire Wainwright is affiliated with the following schools: University of Queensland, University of Melbourne, University of Washington

Claire Wainwright's AcademicInfluence.com Rankings

Claire Wainwright

Philosophy

#10839

World Rank

#14876

Historical Rank

Logic

#7686

World Rank

#9520

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Claire Wainwright's Degrees

Bachelors Medicine University of Melbourne
Masters Paediatrics University of Melbourne

Why Is Claire Wainwright Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Claire E. Wainwright is a paediatric respiratory physician and professor of pediatrics, residing and working in Queensland. She commenced her medical training in London and completed her specialist training at the Royal Children's Hospital, Brisbane. She is now head of the Cystic Fibrosis Service at the Queensland Children's Hospital and a professor of pediatric medicine at the University of Queensland, Australia. Wainwright has published numerous academic papers focusing upon her main area of interest; the impacts of fungal infections upon children with cystic fibrosis. However, her interests also expand to include other airway complications within children.

(See a Problem?)

Claire Wainwright's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. (2011) (1829)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. (2015) (1178)
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. (2013) (446)
Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium (2016) (406)
Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. (2009) (315)
Nebulised hypertonic saline solution for acute bronchiolitis in infants. (2017) (292)
A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis. (2003) (267)
Genetic modifiers of liver disease in cystic fibrosis. (2009) (246)
Nebulized hypertonic saline solution for acute bronchiolitis in infants. (2008) (230)
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). (2014) (193)
Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. (2011) (187)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. (2015) (164)
Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study (2004) (157)
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. (2018) (155)
Series of laryngomalacia, tracheomalacia, and bronchomalacia disorders and their associations with other conditions in children (2002) (144)
Seasonal priority effects: implications for invasion and restoration in a semi-arid system. (2012) (134)
Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units (2004) (134)
Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-element-based PCR assays. (2004) (129)
Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis (2009) (128)
Comparison of DNA Extraction Methods for Microbial Community Profiling with an Application to Pediatric Bronchoalveolar Lavage Samples (2012) (127)
Acute viral bronchiolitis in children- a very common condition with few therapeutic options (2009) (125)
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. (2016) (118)
Phenotypic Characterization of Clonal and Nonclonal Pseudomonas aeruginosa Strains Isolated from Lungs of Adults with Cystic Fibrosis (2007) (112)
Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. (2009) (101)
Effect of Temperature on Cystic Fibrosis Lung Disease and Infections: A Replicated Cohort Study (2011) (99)
Exotic species display greater germination plasticity and higher germination rates than native species across multiple cues (2013) (97)
Long term effects of denufosol tetrasodium in patients with cystic fibrosis. (2012) (93)
Asthma and insulin resistance in children (2010) (92)
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. (2011) (92)
Evidence for Spread of a Clonal Strain of Pseudomonas aeruginosa among Cystic Fibrosis Clinics (2003) (90)
Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis (2005) (85)
A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. (2016) (85)
Nebulized Hypertonic Saline for Acute Bronchiolitis: A Systematic Review (2015) (84)
Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age (2013) (82)
Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis (2014) (81)
Resting energy expenditure, pulmonary inflammation, and genotype in the early course of cystic fibrosis. (1996) (73)
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele (2021) (73)
A clinical pathway for bronchiolitis is effective in reducing readmission rates. (2005) (66)
Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years. (2015) (64)
Nebulised hypertonic saline solution for acute bronchiolitis in infants. (2017) (62)
Disease surveillance using bronchoalveolar lavage. (2008) (61)
Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients (2009) (60)
Links between community ecology theory and ecological restoration are on the rise (2018) (59)
Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres (2012) (58)
Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents and adults with cystic fibrosis: comparison with healthy controls (2003) (56)
Bacterial Causes of Empyema in Children, Australia, 2007–2009 (2011) (55)
Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients (2006) (52)
Face Masks and Cough Etiquette Reduce the Cough Aerosol Concentration of Pseudomonas aeruginosa in People with Cystic Fibrosis (2017) (51)
Infants with chronic neonatal lung disease: recommendations for the use of home oxygen therapy (2008) (48)
Quality-of-life in children and adolescents with cystic fibrosis managed in both regional outreach and cystic fibrosis center settings in Queensland. (2006) (46)
Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patients. (2007) (46)
Safety of bronchoalveolar lavage in young children with cystic fibrosis (2008) (46)
CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis. (2017) (45)
Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial (2020) (45)
A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. (2007) (45)
Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres (2016) (43)
Climate moderates release from nutrient limitation in natural annual plant communities (2015) (42)
Vitamin A levels in patients with CF are influenced by the inflammatory response. (2004) (40)
Daily versus weekly azithromycin in cystic fibrosis patients (2007) (39)
New treatments targeting the basic defects in cystic fibrosis. (2017) (39)
Drivers of seedling establishment success in dryland restoration efforts (2021) (37)
Protease IV production in Pseudomonas aeruginosa from the lungs of adults with cystic fibrosis. (2006) (37)
Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis (2010) (35)
Pubertal development and its influences on bone mineral density in Australian children and adolescents with cystic fibrosis (2005) (34)
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. (2019) (34)
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. (2018) (32)
Factors Influencing Acquisition of Burkholderia cepacia Complex Organisms in Patients with Cystic Fibrosis (2013) (32)
The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. (2017) (31)
Distinct responses of niche and fitness differences to water availability underlie variable coexistence outcomes in semi‐arid annual plant communities (2018) (30)
Aspergillus and progression of lung disease in children with cystic fibrosis (2018) (30)
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial (2021) (29)
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. (2013) (28)
Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients (2015) (27)
Particle and bioaerosol characteristics in a paediatric intensive care unit (2017) (25)
Clinical outcomes of Queensland children with cystic fibrosis: a comparison between tertiary centre and outreach services (2008) (25)
Sources and dynamics of fluorescent particles in hospitals (2017) (25)
Nebulized hypertonic saline solution for acute bronchiolitis in children (2007) (24)
Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis (2013) (23)
The Long Term Efficacy of Gastrostomy Feeding in Children with Cystic Fibrosis on Anthropometric Markers of Nutritonal Status and Pulmonary Function (2009) (22)
A Randomized Controlled Trial of an Interactive Voice Response Telephone System and Specialist Nurse Support for Childhood Asthma Management (2010) (22)
Increased susceptibility of airway epithelial cells from ataxia-telangiectasia to S. pneumoniae infection due to oxidative damage and impaired innate immunity (2019) (21)
Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening. (2013) (21)
Pleural fluid nucleic acid testing enhances pneumococcal surveillance in children (2012) (20)
Ivacaftor for patients with cystic fibrosis (2014) (20)
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. (2021) (20)
Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations. (2020) (20)
Realising opportunities for evidence-based cancer service delivery and research: linking cancer registry and administrative data in Australia. (2014) (19)
Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. (2014) (19)
Inhaled Corticosteroids and Respiratory Infections in Children With Asthma: A Meta-analysis (2017) (19)
Sensitivity of respiratory bacteria to lignocaine (2005) (18)
A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosis (2014) (18)
A bedside assay to detect streptococcus pneumoniae in children with empyema (2011) (18)
Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei (2018) (18)
Loss of ATM in Airway Epithelial Cells Is Associated with Susceptibility to Oxidative Stress (2017) (18)
A Novel Method and Its Application to Measuring Pathogen Decay in Bioaerosols from Patients with Respiratory Disease (2016) (17)
Fosfomycin--investigation of a possible new route of administration of an old drug. A case study. (2007) (17)
A Review of Telemedicine and Asthma (2003) (17)
8. Asthma in children (1997) (16)
Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis (2015) (16)
Segniliparus rugosus Infection, Australia (2009) (15)
Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time PCR and high-resolution melting curve analysis. (2011) (15)
Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients (2018) (15)
Effects of exotic annual grass litter and local environmental gradients on annual plant community structure (2017) (15)
Pseudomonas aeruginosa eradication therapy and risk of acquiring Aspergillus in young children with cystic fibrosis (2019) (15)
Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry (2020) (15)
Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosis. (2014) (14)
A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa (PA) (2010) (14)
Total body water in children with cystic fibrosis using bioelectrical impedance. (2004) (13)
Australasian Cystic Fibrosis BAL study interim analysis (2005) (13)
Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease. (2019) (13)
Differential expression of genes and receptors in monocytes from patients with cystic fibrosis. (2019) (13)
Applied ecological research is on the rise but connectivity barriers persist between four major subfields (2019) (12)
Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis (2021) (12)
Pneumonia in the first 2 years of life, and asthma in preschool‐age children (2011) (12)
Diagnosis and early life risk factors for bronchiectasis in cystic fibrosis: a review (2016) (11)
Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI®): A Short Report (2005) (11)
Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes. (2020) (11)
Preserving Lung Function: The Holy Grail in Managing Cystic Fibrosis. (2017) (11)
Paediatric empyema thoracis: Recommendations for management (2011) (11)
The use of air displacement plethysmography in children and adolescents with cystic fibrosis (2004) (11)
Interim outcomes of a Pseudomonas aeruginosa (Pa) eradication protocol in young children in the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study (2009) (10)
Total bacterial load, inflammation, and structural lung disease in paediatric cystic fibrosis. (2020) (10)
Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia (2021) (10)
High-throughput single-nucleotide polymorphism-based typing of shared Pseudomonas aeruginosa strains in cystic fibrosis patients using the Sequenom iPLEX platform. (2013) (10)
The nutritional status of children with cystic fibrosis (2006) (10)
Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. (2019) (9)
Diverse outcomes of species interactions in an invaded annual plant community (2016) (8)
Year‐in‐review 2010: Asthma, COPD, cystic fibrosis and airway biology (2011) (8)
Trials, tribulations and triumphs of a cystic fibrosis study – a behind the scenes look at the workings of an international multi-centre study (2010) (8)
Multi‐centre research in Australia: Analysis of a recent National Health and Medical Research Council‐funded project (2009) (8)
Supporting Cystic Fibrosis With ICT (2013) (8)
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. (2018) (7)
Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort (2020) (7)
Characteristics of adverse medication events in a children's hospital (2014) (7)
Oxygen saturation targets in infants with bronchiolitis (2015) (7)
Australasian Cf Bronchoalveolar Lavage (acfbal) Study: P. Aeruginosa (pa) Genotypes in Pre-School Cf Children (2011) (6)
Population-level genomics identifies the emergence and global spread of a human transmissible multidrug-resistant nontuberculous mycobacterium (2016) (6)
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study (2022) (6)
Targeted therapy for chronic respiratory disease: a new paradigm (2017) (6)
Evaluating the impact of 2006 Australasian Clinical Practice Guidelines for nutrition in children with cystic fibrosis in Australia. (2018) (6)
‘Someone to talk to’: adolescent and adult CF patients' feedback on their experience of a mentoring and IT intervention (2010) (6)
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. (2022) (6)
Improving self efficacy in adolescents and young adults with cystic fibrosis (CF) (2009) (6)
WS01.3 Lumacaftor in combination with ivacaftor in patients with cystic fibrosis who are homozygous for the F508del-CFTR mutation (2015) (5)
Association Between Changes in Percent Predicted Fev1 and Incidence of Pulmonary Exacerbations, Including Those Requiring Hospitalization And/or IV Antibiotics, in Patients with Cf Treated with Lumacaftor in Combination with Ivacaftor (2015) (5)
Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis. (2021) (5)
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. (2016) (5)
Therapeutic targets and investigated treatments for Ataxia-Telangiectasia (2016) (5)
Pooling of bronchoalveolar lavage in children with cystic fibrosis does not adversely affect the microbiological yield or sensitivity in detecting pulmonary inflammation. (2017) (5)
58 Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with ivacaftor (2013) (5)
Pediatric health, medicine, and therapeutics (2011) (5)
Improved Clinical Outcome After Treatment of Mycobacterium abscessus Complex Pulmonary Disease in Children With Cystic Fibrosis. (2019) (5)
High prevalence of a class 1 integron-associated aadB gene cassette in Pseudomonas aeruginosa isolates from an Australian cystic fibrosis patient population. (2008) (4)
Year in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung disease (2016) (4)
Response to: ‘Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?’ by Jones and Barry (2015) (4)
'Go for it, dream big, work hard and persist': A message to the next generation of CF leaders in recognition of International Women's Day 2020. (2020) (4)
Methods for tracking sagebrush‐steppe community trajectories and quantifying resilience in relation to disturbance and restoration (2019) (4)
Comparison of midline catheters and peripherally inserted central catheters to reduce the need for general anesthesia in children with respiratory disease: A feasibility randomized controlled trial (2021) (4)
Multilocus sequence typing (MLST) of Pseudomonas aeruginosa collected from different ecological niches (2010) (4)
Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging (2014) (4)
Asteraceae invaders have limited impacts on the pollination of common native annual species in SW Western Australia’s open woodland wildflower communities (2015) (4)
143 Lumacaftor/ivacaftor combination therapy in CF patients homozygous for F508del-CFTR with severe lung dysfunction (2015) (4)
Using the General Level Framework to guide training and development needs of pharmacists working in paediatrics (2015) (4)
MODULATION OF MACROPHAGE POLARIZATION AND FUNCTION IN PATIENTS WITH CYSTIC FIBROSIS BY MUTATION-INDEPENDENT IMMUNOMODULATORY COMPOUNDS (2019) (4)
The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. (2022) (4)
Safety and Efficacy of Treatment with Lumacaftor in Combination with Ivacaftor in Patients with Cf Homozygous for F508Del-Cftr (2015) (3)
Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation (2012) (3)
Survival of people with cystic fibrosis in Australia (2022) (3)
What does advanced practice mean to Australian paediatric pharmacists? A focus group study (2015) (3)
Rapid macrolide and amikacin resistance testing for Mycobacterium abscessus in people with cystic fibrosis. (2021) (3)
Current infection control practices used in Australian and New Zealand cystic fibrosis centers (2020) (3)
Outcomes of Health-Mentor Training to improve Self-Management by People with Cystic Fibrosis (CF) (2009) (3)
Face masks and cough etiquette reduce cough-generated bioaerosols containing pseudomonas aeruginosa in patients with cystic fibrosis (2016) (3)
Nontuberculous Mycobacterium (2020) (2)
The Effect of Azithromycin on Structural Lung Disease in Infants with Cystic Fibrosis (COMBAT CF): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Clinical Trial (2021) (2)
Pulmonary Effects Of The Investigational CFTR Potentiator, Ivacaftor, In Two Phase 3 Trials In Subjects With CF Who Have The G551D-CFTR Mutation (2012) (2)
Cough-generated aerosols of Pseudomonas aeruginosa and other Gram Negative Bacteria from cystic fibrosis patients. (2009) (2)
Year in review 2016: Interstitial lung disease, pulmonary vascular disease, pulmonary function, paediatric lung disease, cystic fibrosis and sleep (2017) (2)
Redesign of the Australian Cystic Fibrosis Data Registry: A multidisciplinary collaboration. (2020) (2)
Rapid genotyping of Pseudomonas aeruginosa using repetitive element based PCr assays (2003) (2)
New therapies for people with CF in the CFTR modulator world (2020) (2)
74 Emergence of a shared Pseudomonas aeruginosa strain within an adult cystic fibrosis centre (2016) (2)
Looks can be deceiving: ecologically similar exotics have different impacts on a native competitor (2019) (2)
Uncoupled bone turnover in cystic fibrosis: bone markers and the PTH-vitamin D axis (2002) (2)
Factors in childhood associated with lung function decline to adolescence in cystic fibrosis. (2022) (2)
Spatial Sampling Grain Shapes Conclusions about Community Structure and Dynamics (2020) (2)
Electronic care records - can they fulfil their promise? (2014) (1)
USING THE “GENERAL LEVEL FRAMEWORK” TO IDENTIFY GAPS IN KNOWLEDGE AND SKILLS TO PRIORITISE PROFESSIONAL DEVELOPMENT ACTIVITIES FOR PAEDIATRIC PHARMACISTS (2014) (1)
Effects of exotic annual grass litter and local environmental gradients on annual plant community structure (2016) (1)
Treatment of cystic fibrosis following infant screening (2011) (1)
Alterations of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis. Cystic Fibrosis Transmembrane Conductance Regulator and Antibiotic Effects. (2016) (1)
Identification of The Bacterial Causes of Childhood Empyema in Australia by Enhanced Molecular Surveillance (2010) (1)
Cochrane review: Nebulized hypertonic saline solution for acute bronchiolitis in infants (2010) (1)
WS06-5 Change in low-dose chest Computed Tomography (CT) scores after 72 weeks of tezacaftor/ivacaftor (TEZ/IVA) in patients (pts) with cystic fibrosis and ppFEV1 ≥70%: an exploratory phase 2 study (2019) (1)
Protocol For Study Of Information Needs Of Parents Of Infants Newly Diagnosed With Cystic Fibrosis (2014) (1)
Paediatric population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in cystic fibrosis and bone marrow transplant patients (2006) (1)
A D-optimal designed population pharmacokinetic study of itraconazole capsules and solution in adults with cystic fibrosis (2006) (1)
Kinetic expression of genes and receptors during monocyte to macrophage differentiation in cystic fibrosis (2019) (1)
A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis (2019) (1)
DEVELOPMENT OF THE CYSTIC FIBROSIS QUESTIONNAIRE-REVISED PREFERENCE BASED SCORING ALGORITHM (2019) (1)
Puberty and bone mineral accrual in cystic fibrosis (2002) (1)
Puberty in Cf (2013) (1)
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup (2016) (1)
Neutrophil respiratory burst activity is not exaggerated in cystic fibrosis. (2022) (1)
Life-Threatening Childhood Obesity and Legal Intervention (2016) (1)
WS18.4 Heterogeneity of shared Pseudomonas aeruginosa (Pa) strains between Australian states and centres in cystic fibrosis (CF) (2012) (0)
Real World Impact of 13vPCV in Preventing Invasive Pneumococcal Pneumonia in Australian Children: A National Study (2022) (0)
P156 Nontuberculous mycobacteria infection in people with cystic fibrosis attending cystic fibrosis treatment clinics in Australia (2019) (0)
Outreach Services and Clinics (2008) (0)
Prevalence and impact of oprD mutations in Pseudomonas aeruginosa strains in 1 cystic fibrosis 2 3 (2019) (0)
Repeated Time-to-event Analysis of acquiring Pseudomonas aeruginosa and Aspergillus fumigatus Positive Cultures in Young Children with Cystic Fibrosis Lung Disease. (2016) (0)
Normal fat and lean tissue mass in adults with cystic fibrosis compared with height matched controls (2004) (0)
Body composition assessment in children with cystic fibrosis using air displacement plethysmography (2002) (0)
The wheezing infant (1997) (0)
Presence of epidemic Pseudomonas aeruginosa shared between paediatric and adult cystic fibrosis (2003) (0)
EPS5.07 Evaluating the impact of 2006 clinical practice guidelines for nutrition in children with cystic fibrosis in Australia (2018) (0)
in Patients with Cystic Fibrosis Burkholderia cepacia Complex Organisms Factors Influencing Acquisition of (2014) (0)
Broadening the perspective on the airborne transmission of respiratory infection (2015) (0)
Nebulised hypertonic saline solution for acute bronchiolitis in infants. (2023) (0)
Pharmacokinetic study of itraconazole leads to new improved dosing regimens for paediatric cystic fibrosis and bone marrow transplant patients (2006) (0)
110 A decade of Burkholderia cepacia complex (Bcc) infection in Queensland, Australia: 2001 to 2010 (2012) (0)
Prevalence of shared Mycobacterium abscessus complex in the Queensland cystic fibrosis population. (2018) (0)
Author Correction: Increased susceptibility of airway epithelial cells from ataxia-telangiectasia to S. pneumoniae infection due to oxidative damage and impaired innate immunity (2019) (0)
Proteomic investigations in the young CF lung: new insights into the inflammatory disorder (2005) (0)
Misleading high tobramycin plasma concentrations due to dermal contamination on fingers after inhalation of nebulised tobramycin (TOBI) (2004) (0)
Atypical haemolytic uraemic syndrome in a child with cystic fibrosis (2021) (0)
Clonal pseudomonas aeruginosa (PA) in Australians with cystic fibrosis (CF) (2010) (0)
Information needs and priorities of parents of infants newly diagnosed with cystic fibrosis: a literature review (2014) (0)
Current issues in childhood asthma (part 2) (2000) (0)
Predictive factors of probability of having Aspergillus fumigatus positive culture in bronchoalveolar lavage culture at five years of age of children with cystic fibrosis (2015) (0)
The use of air displacement in plethysmography to measure fat free mass in children (2002) (0)
The nutritional status of children with cystic fibrosis attending the Royal Children's Hospital in Queensland compared to data from the National CF Data Register (2007) (0)
Pharmacological Strategies for the Treatment of the Basic Defect in Cystic Fibrosis (1997) (0)
P058 Prevalence of shared Mycobacterium abscessus complex (MABSC) in the Queensland cystic fibrosis population (2018) (0)
Paediatric population pharmacokinetcis (popPK) of itraconazole (ITRA) and its active metabolite hydroxy-itraconazole in cystic fibrosis (CF) and bone marrow transplant patients (BMT) (2006) (0)
Viability of pseudomonas aeruginosa (Pa) in cough aerosols from adult cystic fibrosis (CF) patients (2013) (0)
Detection of an integron associated aadB resistance gene in Pseudomonas aeruginosa isolates from patients with CF (2005) (0)
Shared Pseudomonas aeruginosagenotypes are common in Australiancystic fibrosis centres (2014) (0)
A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants (2022) (0)
Role of bronchoscopy and bronchoalveolar lavage in infants with cystic fibrosis (2015) (0)
100 (More) viable cough aerosols from individuals with cystic fibrosis (2016) (0)
Pseudomonas aeruginosa antibiotic resistance: comparison between Australian paediatric and adult cystic fibrosis centres (2011) (0)
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations. (2023) (0)
Succession of Non-mucoid Pseudomonas aeruginosa by Mucoid Strains Influences Fungal Colonization in Cystic Fibrosis (2015) (0)
Treatment of pneumonia in childhood (1992) (0)
Seasonal priority effects : implications for invasion and restoration in California coastal sage scrub (2010) (0)
Author Correction: Increased susceptibility of airway epithelial cells from ataxia-telangiectasia to S. pneumoniae infection due to oxidative damage and impaired innate immunity (2020) (0)
Asthma and telemedicine (2005) (0)
MYCOBACTERIUM ABSCESSUS POINT SOURCE OUTBREAK IN THE LOCAL POTABLE WATER SUPPLY AFFECTING PEOPLE WITH CYSTIC FIBROSIS (2019) (0)
Pseudomonas aeruginosa resistance: Comparison between Australian cystic fibrosis (cf) centres (2012) (0)
ALTERNATIVE TRANSMISSION PATHWAYS OF MYCOBACTERIUM ABSCESSUS GROUP (MABS) RESPIRATORY INFECTIONS (2020) (0)
Author Correction: Drivers of seedling establishment success in dryland restoration efforts (2021) (0)
Misleading high tobramycin blood levels due to dermal contamination on fingers after inhalation of TOBI (2004) (0)
NON-TUBERCULOUS MYCOBACTERIA INFECTION IN PEOPLE WITH CYSTIC FIBROSIS ATTENDING CF TREATMENT CLINICS IN AUSTRALIA (2019) (0)
Bronchoalveolar Lavage–Directed Therapy in Children With Cystic Fibrosis and Pseudomonas aeruginosa Infection—Reply (2011) (0)
Potable water as a possible source of Mycobacterium abscessus complex infection in people with cystic fibrosis. (2018) (0)
Comparison of multilocus sequence typing (MLST), pulse field gel electrophoresis (PFGE), and enterobacterial intergenic consenus PCR (ERIC) for the genotypic analysis of Pseudomonas aeruginosa isolates collected from persons with cystic fibrosis (CF) (2009) (0)
Vitamin d status and bone mineral density in an australian cystic fibrosis population (2001) (0)
Exotic species display greater germination plasticity and higher germination rates than native species across multiple cues (2013) (0)
Current issues in childhood asthma. Part 2: questions and answers (2000) (0)
A New Era for Cystic Fibrosis and CFTR Modulator Trials in Infants. (2022) (0)
Respiratory exacerbations in children aged 0–3 years in the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study (2009) (0)
Characteristics of particles concentration in a Paediatric Intensive Care Unit (PICU) (2016) (0)
Quality of life in people with cystic fibrosis whilst clinical stable (2008) (0)
P159 Factors associated with Mycobacterium abscessus group (MABS) infection type in people with cystic fibrosis (2019) (0)
WS01.1 A phase 3, 2-part, single-arm study of ivacaftor treatment in patients <2 years with a CFTR gating mutation: results from the ARRIVAL study in patients 1 to 2 years (2018) (0)
Information communication technology in cystic fibrosis support (2012) (0)
P456 Health related quality of life outcomes for children in the Australasian Cystic Fibrosis Bronchoalveolar Lavage study (2019) (0)
A Retrospective Study of Gastrointestinal Malignancy in Australian and New Zealand Cystic Fibrosis (Cf) Patients (2012) (0)
Development of the CFQ-R-8D: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised. (2021) (0)
Mentoring people with cystic fibrosis: evaluation of the preparation and process (2009) (0)
Repeated time-to-event models support that Pseudomonas aeruginosa infection increase the risk of acquiring Aspergillus in young children with cystic fibrosis (2019) (0)
STEROID INJECTIONS FOR LUMBAR RADICULOPATHY – A CONTENTIOUS BUT EFFECTIVE TREATMENT (2005) (0)
OPEN-LABEL EXTENSION STUDY: TEZACAFTOR/IVACAFTOR, PATIENTS >= 12 YEARS WITH CYSTIC FIBROSIS (2020) (0)
Adverse drug events in children: using voluntary reports to measure the impact of medication safety initiatives in an Australian pediatric hospital (2012) (0)
Identifying the Bacterial Causes of Childhood Empyema in Australia (2008) (0)
Species interactions and the formation of novel annual plant communities following rapid environmental change (2015) (0)
Australasian CF bronchoalveolar lavage (ACFBAL) Study: Pseudomonas aeruginosa (Pa) genotypes in pre-school CF children (2011) (0)
Long-term SUCCESS: Vegetation data collected in 2017 from permanent plots in the sagebrush steppe of south-central Washington state (0)
183 Chest computed tomography assessment to monitor cystic fibrosis structural lung disease progression in bronchiectasis during late childhood and adolescence (2022) (0)
Measures of Ventilation Inhomogeneity in Children With Cystic Fibrosis: Intra-breath Oscillometry Vs. MBW (2023) (0)
High-throughput single-nucleotide polymorphismbasedtyping of shared Pseudomonas aeruginosastrains in cystic fibrosis patients using theSequenom iPLEX platform (2014) (0)
Environmental origins of Pseudomanos aeruginosa in children with cystic fibrosis (2011) (0)
The hazard of Aspergillus fumigatus positive culture in young children with cystic fibrosis (2015) (0)
Aztreonam Lysine: An Inhalational Antibiotic in Cystic Fibrosis (2011) (0)
Genetic adaptation of Pseudomonas aeruginosa to the airways of two Australian cystic fibrosis patients (2011) (0)
Widespread prevalence of related Pseudomonas aeruginosa strains within Australian cystic fibrosis centres (2011) (0)
Prevalence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis (2019) (0)
Multilocus sequence typing (MLST) of Pseudomonas aeruginosa (2010) (0)
Resistin and airway inflammation in children with allergic asthma (2009) (0)
Cystic Fibrosis Cellular Treatments (2021) (0)
CFTR-dependent deficiency in alternatively-activated macrophages in cystic fibrosis (2016) (0)
Centralised versus outreach models of cystic fibrosis care should be tailored to the needs of the individual patient (2020) (0)
Current issues in childhood asthma. Part 1: diagnosis and management (2000) (0)
Pooling of Bronchoalveolar Lavage in Children with Cystic Fibrosis Does Not Affect the Microbiological Yield and May Allow Earlier Detection of Pulmonary Inflammation (2016) (0)
The changing prevalence of clonal strains of Pseudomonas aeruginosa (Psa) at two Australian CF centres (2008) (0)
Test your knowledge – sexually transmitted diseases (2000) (0)
Heterogeneity of Shared P. Aeruginosa (pa) Strains Across States and Centres in Cystic Fibrosis (2012) (0)
TITLE: Prevalence and impact of oprD mutations in Pseudomonas aeruginosa strains in 1 cystic fibrosis 2 (2019) (0)
Acquired aminoglycoside resistance in pseudomonas aeruginosa from a cystic fibrosis patient (2012) (0)
Buddy system for nursing students: two practice focused approaches to peer support (2003) (0)
Asthma in children (1997) (0)
HIGH INCIDENCE OF NON-TUBERCULOUS MYCOBACTERIA-POSITIVE CULTURES AMONG CHILDREN WITH CYSTIC FIBROSIS IN AUSTRALIA (2019) (0)
Airway inflammation and lung function in cystic fibrosis. (2023) (0)
Loss of virulence expression of pseudomonas aeruginosa from cystic fibrosis lung infection over time (2011) (0)
Burkholderia cepacia complex infection (bcc) in cystic fibrosis (cf): 2001-2010 (2012) (0)
Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis (2013) (0)
P174 High aerosol production of potentially infectious cough aerosols in people with cystic fibrosis during coughing (2019) (0)
THE IMPACT OF THE 13 VALENT CONJUGATE PNEUMOCOCCAL VACCINE ON PNEUMOCOCCAL SEROTYPES CAUSING CHILDHOOD EMPYEMA IN AUSTRALIA (2018) (0)
Evaluating the impact of clinical practice guidelines for nutrition in children with cystic fibrosis in Australia (2018) (0)
Adverse events associated with flexible bronchoscopy (FB) and bronchoalveolar lavage (BAL) in young children with cystic fibrosis (2005) (0)
WS02.2 Prevalence of nontuberculous mycobacteria in potable water (2018) (0)
Use of Positive Expiratory Pressure physiotherapy in Australian children with cystic fibrosis under five years of age (2010) (0)
The influence of pulmonary infection on lung function in infants with cystic fibrosis. (1999) (0)
Nontuberculous Mycobacteria in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Regulator Modulators (2023) (0)
Body cell mass adjustment for stature in children with clinical conditions (2005) (0)
S63 Ivacaftor in 4- to <6-month-old infants with cystic fibrosis and a gating mutation: results of a 2-part, single-arm, Phase 3 study (2021) (0)
Asteraceae invaders have limited impacts on the pollination of common native annual species in SW Western Australia’s open woodland wildflower communities (2015) (0)
The effect of gastrostomy feeding on markers of nutritional status in children with cystic fibrosis (2007) (0)
Volume-dependence of Reactance as a Measure of Ventilation Inhomogeneity in Cystic Fibrosis (2023) (0)

This paper list is powered by the following services:

Other Resources About Claire Wainwright

en.wikipedia.org

What Schools Are Affiliated With Claire Wainwright?

Claire Wainwright is affiliated with the following schools:

Claire Wainwright's Academic­Influence.com Rankings